NSPRHealthcare · Medical DevicesThe 3 Wall Street analysts covering InspireMD, Inc. hold a median 12-month price target of $3 — +246.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores InspireMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NSPR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +246.7% from it.
Of the 11 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 May 2026 | Piper Sandler | Reiterates | Overweight | $4.00 → $3.00 |
| 12 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2024 | Lake Street | Initiates | Buy | — |
| 17 Sept 2024 | Piper Sandler | Reiterates | Overweight | $4.50 |
| 2 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 12 June 2023 | Piper Sandler | Initiates | Overweight | — |
| 17 May 2023 | National Alliance Securities | Maintains | Buy | — |
| 31 Mar 2023 | Alliance Global Partners | Maintains | Buy | — |
| 16 Oct 2020 | Alliance Global Partners | Initiates | Buy | $0.70 |
| 11 Mar 2020 | HC Wainwright & Co. | Reiterates | Buy | $5.00 → $2.00 |
| 29 Mar 2016 | Rodman & Renshaw | Maintains | Buy | $4.00 → $3.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NSPR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 34% of US stocks
Cheaper than 82% of US stocks
Cheaper than 62% of US stocks
Higher than 94% of US stocks
Higher than 86% of US stocks
Higher than 21% of US stocks
Higher than 8% of US stocks
Higher than 89% of US stocks
Higher than 9% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own InspireMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
InspireMD (NSPR) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade signals increased confidence in the company's near-term outlook.
Why it matters — A Zacks upgrade to Buy indicates improved analyst sentiment on InspireMD's earnings outlook, which NSPR watchers would consider a favorable signal.
Seeking Alpha published the Q2 2026 earnings call transcript for InspireMD, Inc. (NSPR). The transcript covers the company's second-quarter 2026 results and management discussion during the earnings call.
Why it matters — A NSPR watcher would care because the earnings call transcript provides direct management commentary on the company's latest quarterly performance and outlook.
InspireMD announced its financial and operating results for the three and six months ended June 30, 2026, reporting second-quarter revenue of $1.8 million, in line with the same period in 2025. The company also scheduled an investor conference call for August 17 at 8:30 a.m. EDT.
Why it matters — NSPR watchers would care because the results provide an update on the company's revenue performance for the CGuard Prime carotid stent system.
InspireMD, Inc. (NSPR) reported a second-quarter net loss of $0.17 per share, which was narrower than the Zacks Consensus Estimate of a $0.20 loss and improved from a $0.26 per-share loss a year earlier. The company also beat revenue expectations for the quarter.
Why it matters — NSPR watchers would note the smaller-than-expected quarterly loss and top-line revenue beat, signaling financial results ahead of analyst projections.
InspireMD announced that its Compensation Committee approved inducement grants of 221,666 restricted stock shares to a new non-executive employee, granted under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with a grant date of August 3, 2026.
Why it matters — A NSPR watcher would care because this shows the company is attracting new talent by offering equity incentives, which may signal continued business development while slightly expanding the share base.
The 3 Wall Street analysts covering InspireMD, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering InspireMD, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InspireMD, Inc. 53 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, InspireMD, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +246.7% from the last close, and Ticker Nerd's factor model ranks InspireMD, Inc. 53 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering InspireMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.
InspireMD, Inc. returned -63.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
InspireMD Inc. is a leading medical device company focusing on innovative embolic prevention systems and neurovascular devices.
The most recent item we track (Zacks Investment Research, 20 Aug 2026): "InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know". InspireMD (NSPR) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade signals increased confidence in the company's near-term outlook.
InspireMD Inc. is a leading medical device company focusing on innovative embolic prevention systems and neurovascular devices. Its primary mission is to improve the outcome of vascular procedures with its proprietary MicroNet™ technology, which is designed to significantly improve the efficacy and safety of stenting procedures. InspireMD is particularly influential in the interventional cardiology and neurovascular sectors, targeting severe cardiovascular conditions such as carotid artery disease and coronary artery disease. The company is headquartered in Tel Aviv, Israel, and serves a global market, distributing its products in numerous countries. As a key player in the medical device industry, InspireMD strives to reduce the risks associated with stenting, such as embolization and restenosis, thus aiming to enhance patient care and safety in critical medical interventions. Its commitment to advancing medical technology makes InspireMD a pivotal entity in the ongoing effort to innovate and improve healthcare delivery worldwide.
CEO Mr. Marvin L. Slosman · 127 employees · United States · https://www.inspiremd.com